BioSpace News Archive

Company CEO Recognized for Launching US Outpost for Korea’s Samyang Pharmaceuticals and Innovative Leadership, Ability to Attract R&D Partnerships

Increased fiscal 2021 Adjusted Earnings per diluted share guidance range to $14.70 to $15.50, from the previous range of $13.95 to $14.75.

GTCR, a leading private equity firm, announced that its TerSera Therapeutics LLC portfolio company has entered into a definitive agreement to acquire the product Xermelo® from Lexicon Pharmaceuticals, Inc. for an upfront purchase price of approximately $159 million plus potential milestone payments based on development and commercialization of Xermelo in a new indication.

Graybug Vision, Inc. announced the appointment of leading ophthalmologists and retinal experts to provide external scientific counsel on the company’s research and development programs.

Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarter ended June 30, 2020. Clinical Pipeline Update Roluperidone On May 29, 2020, the Company announced that the Phase 3 trial of roluperidone to treat negative symptoms in schizophrenia did not

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced it will release second quarter and first half 2020 financial results after the market closes on Monday, August 10 th , 2020. The Company will host a con

Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that it will report its second quarter 2020 financial results at the opening of U.S. financial markets on Monday, August 10, 2020. Neos management will host a conference call and live audio webcast to discuss these results and provide a company update at 8:30 a.m. E

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release second quarter 2020 financial results after market close on Monday, August 10, 2020. Further, Catalyst management will host an investment-community conferenc

SD-101 is a proprietary investigational, second-generation, Toll-like receptor 9 (TLR9) agonist CpG-C class oligodeoxynucleotide

Celldex Therapeutics, Inc. (Nasdaq:CLDX) will report second quarter 2020 financial results on Thursday, August 6, 2020 after the U.S. financial markets close. Celldex executives will host a conference call at 4:30 p.m. EDT on the same day to review the second quarter financial results and to provide an update on key research and development and business objectives for the remainder of 2020. The conference call and presentation will be webcast